BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GENEWIZ, Inc. Launches OncoGxOne™ Discovery Cancer Panels


4/8/2013 9:17:12 AM

SOUTH PLAINFIELD, NJ--(Marketwired - April 07, 2013) - GENEWIZ, Inc., leading global genomics service provider, announced the launch of OncoGxOne™ Discovery cancer panels, proprietary gene panels designed specifically to assay genomic aberrations for all major cancer types.

Designed and developed by experts with the most recent research data available, GENEWIZ OncoGxOne™ Discovery cancer panels are the most comprehensive cancer-specific gene panels on the market, and have the ability to detect all types of genomic aberrations, including point mutations, Indels, gene fusions, and copy number variance (CNV).

"With the launch of OncoGxOne™ Discovery cancer panels, GENEWIZ has the opportunity to drive advancements in cancer research, offering solutions for biomarker discovery, therapeutic target discovery, and novel mutation identification," stated Dr. Guanghui Hu, Vice President of Translational Genomics.

"Using the latest next generation sequencing and bioinformatics technologies, OncoGxOne™ Discovery cancer panels can detect not only low-frequency variations and gene fusions in both exon and intron regions, but also CNV with great accuracy," Hu asserted. "The resulting data has the ability to stratify patients in clinical trials, as well as make a significant impact on personalized cancer treatment."

For more information about GENEWIZ OncoGxOne™ Discovery cancer panels, visit GENEWIZ at the American Association for Cancer Research (AACR) Annual Meeting this week in Washington, D.C.

About GENEWIZ, Inc.
GENEWIZ, Inc. is a global contract research organization (CRO) specializing in genomic services, including DNA sequencing, gene synthesis, molecular biology, genomic, bioinformatics, and GxP/CLIA regulatory-compliant services. GENEWIZ leads the industry in outsourcing partnerships with pharmaceutical, biotechnology, clinical, academic, and government institutions.

Headquartered in South Plainfield, NJ, GENEWIZ, Inc. is a privately-held global enterprise with locations in Boston, MA; San Diego, CA; Washington, DC Metro; Research Triangle Park, NC; and Seattle, WA. International locations include Beijing, China; Suzhou, China; and London, United Kingdom.


GENEWIZ, Inc.
Email Contact
Global Headquarters
115 Corporate Boulevard
South Plainfield, NJ 07080
+1-908-222-0711
www.genewiz.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES